Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension E-03 to Protocol RAD001AB253 in de novo heart transplant recipients
2005-004908-36Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of everolimus in Cardiac Rejection (3 arms), sponsored by Novartis. Primary endpoint: Survival status and major adverse cardiac events (MACE). Started Jan 2007; status: completed.
02
Drugs
everolimus
03
Conditions
Cardiac Rejection
Beyond the preview
Go deeper on 2005-004908-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004908-36.